# US 2016/0252527 A1 · Assays for determining plasma kallikrein system biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252527 A1
- Document ID: US20160252527A1
- Status: Published application
- Kind: A1
- Application number: 15/030,811
- Filed: 2014-10-17
- Published: 2016-09-01
- Earliest claimed: 2013-10-21
- Assignees: Dyax Corp.
- Applicants: Dyax Corp.
- Inventors: Daniel J. Sexton; Ryan Faucette; Jon A. Kenniston; Gregory P. Conley; Andrew Nixon; Christopher TenHoor; Burt Adelman
- Web page: https://patentgrep.com/patent/US20160252527A1

## CPC

- A61P 7/10: Antioedematous agents; Diuretics
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/36: against blood coagulation factors
- C07K 16/40: against enzymes
- C12Q 1/37: involving peptidase or proteinase
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Y 304/21034: Plasma kallikrein (3.4.21.34)
- C12Y 304/21038: Coagulation factor XIIa (3.4.21.38)
- G01N 2333/4713: Plasma globulins, lactoglobulin
- G01N 2333/96455: Kallikrein (3.4.21.34; 3.4.21.35)
- G01N 2333/96458: Factor XII (3.4.21.38)
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/20: cell-free systems
- G01N 2800/224: Haemostasis or coagulation
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

## Claims

### Claim 1

An ex vivo activation method, comprising:
incubating a plasma sample obtained from a subject with an activator of the plasma kallikrein (pKal) system;
measuring the levels of intact high molecular weight kininogen (HMWK), cleaved HMWK, or both, in the plasma sample before and after the incubation; and
determining the reduction of intact HMWK in the sample after the activation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the levels of intact HMWK and cleaved HMWK are measured by Western blot analysis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Western blot analysis is Protein Simple Western blot analysis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the activator is Factor FXIIa.

### Claim 5 (depends on 1)

The method of any of claim 1, wherein the plasma sample and the activator are incubated in the presence of a pKal modulator candidate.

### Claim 6 (depends on 5)

The method of claim 5, further comprising assessing the activity of the pKal inhibitor candidate on plasma kallikrein.

### Claim 7 (depends on 5)

The method of claim 5, wherein the pKal modulator candidate is a pKal inhibitor candidate.

### Claim 8 (depends on 1)

The method of any of claim 1, further comprising assessing whether the subject has or is at risk for a disease associated with pKal; wherein an elevated level of the cleaved HMWK as compared to a predetermined value indicates that the subject has or is at risk for the disease.

### Claim 9 (depends on 8)

The method of claim 8, wherein the disease is HAE.

### Claim 10 (depends on 1)

The method any of claim 1, wherein the subject is a human patient having a disease associated with pKal and is subjected to a treatment of the disease; and wherein the plasma sample is obtained after or during the course of the treatment.

### Claim 11 (depends on 10)

The method of claim 10, further comprising evaluating the efficacy of the treatment; wherein a reduced level of cleaved HMWK as to compared that before the treatment or a reduced level of cleaved HMWK over the course of the treatment indicates that the treatment is effective.

### Claim 12 (depends on 10)

The method of claim 10, wherein the patient has HAE and is treated with a pKal inhibitor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pKal inhibitor is DX2930.

### Claim 14

A method for assessing plasma activation in a subject, comprising:
providing a plasma sample from a subject; and
measuring the level of cleaved HMWK in the plasma sample.

### Claim 15 (depends on 14)

The method of claim 14, wherein the level of cleaved HMWK is measured by Western blot analysis.

### Claim 16 (depends on 15)

The method of claim 15, wherein the Western blot analysis is Protein Simple Western blot analysis.

### Claim 17 (depends on 14)

The method of any of claim 14, wherein the subject has or is suspected of having a disease associated with the plasma kallikrein (pKal) system.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject is treated with a pKal inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, further comprising evaluating the efficacy of the pKal inhibitor, wherein a reduced level of cleaved HMWK after the treatment as compared with that before the treatment indicates that the pKal inhibitor is effective.

### Claim 20 (depends on 14)

The method of any of claim 14, further comprising assessing whether the subject has or is at risk for a disease associated with pKal; wherein an elevated level of the cleaved HMWK as compared to a predetermined value indicates that the subject has or is at risk for the disease.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disease is HAE.

### Claim 22 (depends on 14)

The method any of claim 14, wherein the subject is a human patient having a disease associated with pKal and is subjected to a treatment of the disease; and wherein the plasma sample is obtained after or during the course of the treatment.

### Claim 23 (depends on 22)

The method of claim 22, further comprising evaluating the efficacy of the treatment; wherein a reduced level of cleaved HMWK as to compared that before the treatment or a reduced level of cleaved HMWK over the course of the treatment indicates that the treatment is effective.

### Claim 24 (depends on 22)

The method of claim 22, wherein the patient has HAE and is treated with a pKal inhibitor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the pKal inhibitor is DX2930.

### Claim 26

An ex vivo assay for determining plasma kallikrein (pKal) activity in a sample, comprising:
incubating the sample with a pKal system activator in the presence of a pKal substrate, and
measuring the activity of pKal based on the cleavage rate of the substrate.

### Claim 27 (depends on 26)

The assay of claim 26, wherein the sample is a plasma sample from a subject.

### Claim 28 (depends on 26)

The assay of claim 26, wherein the substrate is attached to a label, which is capable of releasing a detectable signal after being cleaved by pKal and the cleavage rate of the substrate is determined based on the magnitude of the detectable signal.

### Claim 29 (depends on 26)

The assay of claim 26, wherein the activator is Factor XIIa.

### Claim 30 (depends on 26)

The assay of claim 26, wherein the plasma sample is incubated with the activator, the pKal substrate, and a pKal modulator candidate.

### Claim 31 (depends on 30)

The assay of claim 30, wherein the pKal modulator candidate is a pKal inhibitor candidate.

### Claim 32 (depends on 31)

The assay of claim 31, further comprising evaluating the inhibitory activity of the pKal inhibitor candidate on pKal, wherein a reduced level of pKal activity in the presence of the pKal inhibitor candidate as related to the level of pKal activity in the absence of the pKal inhibitor candidate indicates that the inhibitor candidate is effective.

### Claim 33 (depends on 30)

The assay of claim 30, wherein the pKal inhibitor is an antibody that binds pKal.

### Claim 34 (depends on 33)

The assay of claim 33, wherein the antibody is DX-2930.

### Claim 35 (depends on 26)

The assay of claim 26, further comprising assessing whether the subject has or is at risk for a disease associated with pKal; wherein an elevated level of pKal activity as compared to a predetermined value indicates that the subject has or is at risk for the disease.

### Claim 36 (depends on 35)

The assay of claim 35, wherein the disease is HAE.

### Claim 37 (depends on 26)

The assay of claim 26, wherein the subject is a human patient having a disease associated with pKal and is subjected to a treatment of the disease; and therein the sample is obtained after or during the course of the treatment.

### Claim 38 (depends on 37)

The assay of claim 37, further comprising evaluating the efficacy of the treatment; wherein a reduced level of pKal activity as to compared that before the treatment or a reduced level of pKal activity over the course of the treatment indicates that the treatment is effective.

### Claim 39 (depends on 37)

The assay of claim 37, wherein the patient has HAE and is treated with a pKal inhibitor.

### Claim 40 (depends on 39)

The assay of claim 39, wherein the pKal inhibitor is DX2930.

### Claim 41 (depends on 26)

The assay of claim 26, wherein the assay is performed in a microplate.
